Back to Protocols & Dosing
Protocols & Dosing10 min read

TB-500 Reconstitution and Dosing: Thymosin Beta-4 in the Literature

Educational map of TB-500 versus thymosin beta-4: how lyophilized vials are discussed, what wound-healing and cardiac papers actually studied, and research-reference ranges versus community loading tables.

PeptIQ Team
Peptide Research & Education
TB-500 Reconstitution and Dosing: Thymosin Beta-4 in the Literature

PeptIQ app

Calculate your TB-500 reconstitution in PeptIQ

Stop guessing syringe math. Log vials, BAC water, and doses — then track every injection free.

Get the app — freeOpen free web app

Free · iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Explore providers

Telehealth assessments for compounds mentioned on this page. PeptIQ may earn a referral fee. Not medical advice.

Module 2 — Dose, schedule, and stacks

Lesson 7 of 8 in Hands-on protocols

  • Build a weekly schedule around half-life
  • Understand stacking logic and washouts
Up next: Recovery stack planning

# TB-500 Reconstitution and Dosing: Thymosin Beta-4 in the Literature

> Note: PeptIQ is not a medical provider. This article is educational only. Figures from papers and community logs are not a protocol.

TB-500 is the name most research-vial listings use for a synthetic fragment associated with thymosin beta-4, a 43-amino-acid peptide present in many mammalian cells. Goldstein and Kleinman reviewed thymosin beta-4 as a multifunctional wound-healing peptide (PubMed 20507180). Cardiac and angiogenesis papers describe a broader biology than the "loading then cruise" tables that dominate forums (PubMed 22823621).

The naming mismatch matters. A vial labeled TB-500 is not automatically the same material, salt, or fill weight used in a thymosin beta-4 clinical or preclinical paper. Reconstitution math assumes the label is true. That assumption is often the weakest part of the story.

Evidence tier

LayerStrengthLimit
Thymosin beta-4 reviewsMechanism and wound/angiogenesis framingParent peptide, not every TB-500 listing
Cardiac and regeneration papersSpecific models and endpointsNot a consumer loading calendar
Community logsWhat people record as mg and weekly cadenceObservational only

ClinicalTrials.gov indexes thymosin beta-4 studies (search). Registry rows are not a reconstitution recipe.

Lyophilized-vial arithmetic

Educational summaries treat a TB-500 vial the same way they treat other freeze-dried peptides:

Concentration (mg/mL) = labeled milligrams ÷ diluent milliliters

Draw volume (mL) = intended milligrams ÷ concentration

Illustrative example only

A vial labeled 5 mg reconstituted with 2 mL bacteriostatic water is 2.5 mg/mL. A 2.5 mg draw would be 1.0 mL (100 units on a U-100 syringe). A 2.0 mg draw would be 0.80 mL. A 10 mg vial with the same 2 mL of water is 5 mg/mL, so the same milligram target is a smaller volume.

Those conversions explain why two people "on 2.5 mg" can be holding different unit counts. They are not instructions to mix a vial.

Bacteriostatic water is the diluent named most often in community education for multi-draw vials. Product-specific guidance, when it exists, outranks that habit. Storage language is usually lyophilized cold and dark, reconstituted refrigerated, with a conservative beyond-use window measured in weeks rather than months.

What papers report versus what forums schedule

Thymosin beta-4 literature discusses systemic and local exposure in healing and cardiac models. Dose, route, and duration follow the experiment, not a two-week load. Reviews summarize angiogenesis, cell migration, and anti-inflammatory signals. They do not publish a universal milligram-per-week consumer schedule.

Community tables usually split a "loading" block from a lower-frequency "maintenance" block, often in the low-milligram range a few times per week. PeptIQ users who log TB-500 tend to record less-frequent entries than they do for BPC-157, which matches the longer-acting narrative people repeat. That is a logging pattern. It is not a finding that loading works.

SourceFigure people citeHonest reading
Forum loading tablesMulti-milligram doses, 2x/week for a few weeksUncontrolled convention
In-app TB-500 logsFewer weekly events than BPC-157Observational cadence
Thymosin beta-4 papersStudy-specific regimensNot transferable to an unlabeled vial

Route language in third person

Published work has used several parenteral routes depending on the model. Community education talks about subcutaneous administration because that is how research vials are handled in those discussions. That is route sociology, not an injection tutorial. Needle size, site maps, and sterile technique are outside the scope of this page.

BPC-157 and TB-500 are often logged in the same week. Compatibility claims about drawing two reconstituted solutions into one syringe are chemistry and sterility questions, not a reason to treat either compound as settled. See the mixing and stacking explainers for that context.

Bottom line

TB-500 listings ride on thymosin beta-4 science they may not chemically match. Reconstitution math is generic. Loading calendars are community artifacts. The papers are real. The protocol-shaped tables are not.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections, calculate doses, access our peptide library, and optimize your protocols.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy